[go: up one dir, main page]

WO1997007819B1 - Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter - Google Patents

Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter

Info

Publication number
WO1997007819B1
WO1997007819B1 PCT/EP1996/003733 EP9603733W WO9707819B1 WO 1997007819 B1 WO1997007819 B1 WO 1997007819B1 EP 9603733 W EP9603733 W EP 9603733W WO 9707819 B1 WO9707819 B1 WO 9707819B1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cells
antigen
receptor
pharmaceutical composition
Prior art date
Application number
PCT/EP1996/003733
Other languages
German (de)
English (en)
Other versions
WO1997007819A1 (fr
Filing date
Publication date
Priority claimed from DE19531346A external-priority patent/DE19531346A1/de
Application filed filed Critical
Priority to AT96929318T priority Critical patent/ATE208630T1/de
Priority to US09/029,369 priority patent/US6294167B1/en
Priority to EP96929318A priority patent/EP0845998B1/fr
Priority to DK96929318T priority patent/DK0845998T3/da
Priority to DE59608213T priority patent/DE59608213D1/de
Publication of WO1997007819A1 publication Critical patent/WO1997007819A1/fr
Publication of WO1997007819B1 publication Critical patent/WO1997007819B1/fr

Links

Abstract

L'invention concerne des médicaments contenant des anticorps présentant au moins une spécificité, qui identifient l'antigène du MCHII d'un patient à traiter. L'invention concerne en outre des anticorps présentant deux spécificités ou plus, qui identifient l'antigène MCHII d'un patient, ainsi que des compositions diagnostiques contenant lesdits anticorps.
PCT/EP1996/003733 1995-08-25 1996-08-23 Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter WO1997007819A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT96929318T ATE208630T1 (de) 1995-08-25 1996-08-23 Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen
US09/029,369 US6294167B1 (en) 1995-08-25 1996-08-23 Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated
EP96929318A EP0845998B1 (fr) 1995-08-25 1996-08-23 Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter
DK96929318T DK0845998T3 (da) 1995-08-25 1996-08-23 Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
DE59608213T DE59608213D1 (de) 1995-08-25 1996-08-23 Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19531346A DE19531346A1 (de) 1995-08-25 1995-08-25 Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
DE19531346.1 1995-08-25

Publications (2)

Publication Number Publication Date
WO1997007819A1 WO1997007819A1 (fr) 1997-03-06
WO1997007819B1 true WO1997007819B1 (fr) 1997-05-15

Family

ID=7770409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/003733 WO1997007819A1 (fr) 1995-08-25 1996-08-23 Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter

Country Status (8)

Country Link
US (1) US6294167B1 (fr)
EP (1) EP0845998B1 (fr)
AT (1) ATE208630T1 (fr)
DE (2) DE19531346A1 (fr)
DK (1) DK0845998T3 (fr)
ES (1) ES2164914T3 (fr)
PT (1) PT845998E (fr)
WO (1) WO1997007819A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368596B1 (en) * 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
DE19937264A1 (de) * 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶-Antikörper-Konstrukte
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
US6894149B2 (en) * 2001-10-11 2005-05-17 Protein Design Labs, Inc. Anti-HLA-DA antibodies and the methods of using thereof
DE10261223A1 (de) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
GB0509318D0 (en) * 2005-05-06 2005-06-15 Chiron Srl TCR-independent activation of T cells
GB0512225D0 (en) * 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
EP1820513A1 (fr) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction des cellules tumorales exprimant à un niveau bas ou moyen des antigènes cibles associés aux tumeurs, par des anticorps trifonctionels bispécifiques
WO2008016431A2 (fr) 2006-07-29 2008-02-07 Robert Lamar Bjork Médicament thérapeutique d'anticorps monoclonal bispécifique ( spécifique à la fois à cd3 et cd11b)
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
EP2241576A1 (fr) 2009-04-17 2010-10-20 Trion Pharma Gmbh Utilisation des anticorps bispécifiques trifonctionnels pour le traitement des tumeurs associées aux cellules souches de cancer CD133+/EpCAM+
RU2760005C2 (ru) * 2014-03-13 2021-11-22 Университет Базель УГЛЕВОДНЫЕ ЛИГАНДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С IgM АНТИТЕЛАМИ ПРОТИВ МИЕЛИН-АССОЦИИРОВАННОГО ГЛИКОПРОТЕИНА
BR112019010878A2 (pt) 2016-11-29 2019-10-01 Lindhofer Horst combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
AU2018220736B2 (en) 2017-02-20 2024-10-24 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
JP7690286B2 (ja) 2018-02-08 2025-06-10 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ受容体を標的とする抗体可変ドメイン
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
US12215157B2 (en) 2018-02-20 2025-02-04 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
CA3108427A1 (fr) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteines de liaison multi-specifiques se liant a bcma, nkg2d et cd16, et methodes d'utilisation
MA53284A (fr) 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
EP4301774A4 (fr) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc Méthodes de traitement du cancer à l'aide de protéines de liaison multi-spécifiques qui se lient à nkg2d, à cd16 et à un antigène associé à une tumeur

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269354D1 (en) 1981-06-25 1986-04-03 Univ Leland Stanford Junior Allele specific immunotherapeutic method and dosage form
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies

Similar Documents

Publication Publication Date Title
WO1997007819B1 (fr) Medicaments s'utilisant en immunotherapie et contenant des anticorps identifiant specifiquement l'antigene du mhcii d'un patient a traiter
Mason et al. LGL-1: a non-polymorphic antigen expressed on a major population of mouse natural killer cells.
Reinherz et al. Antibody directed at a surface structure inhibits cytolytic but not suppressor function of human T lymphocytes
Weiss et al. Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line.
US6294167B1 (en) Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated
Bonnefoy et al. The low-affinity receptor for IgE (CD23) on B lymphocytes is spatially associated with HLA-DR antigens.
EP0403156B1 (fr) Anticorps monoclonaux améliorés contre le récepteur alpha/bêta des cellules T humaines, leur production et leur utilisation
US5885573A (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FI117900B (fi) Menetelmä solun valmistamiseksi, joka ilmentää soluvälitteisen immuuniteetin uudelleensuuntaavia reseptorikimeeroja, ja niitä koodaava DNA ja vektori
EP2070948B1 (fr) Anticorps anti-CD4 humanisé doté de propriétés immunosuppressives
Schiller et al. CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells
Rebai et al. Distinct HLA‐DR epitopes and distinct families of HLA‐DR molecules defined by 15 monoclonal antibodies (mAb) either anti‐DR or allo‐anti‐Iak crossreacting with human DR molecule. I. Cross‐inhibition studies of mAb cell surface fixation and differential binding of mAb to detergent‐solubilized HLA molecules immobilized to a solid phase by a first mAb
Spertini et al. Induction of human T cell proliferation by a monoclonal antibody to CD5.
Pauza et al. Unusual patterns of immunoglobulin gene rearrangement and expression during human B cell ontogeny: human B cells can simultaneously express cell surface kappa and lambda light chains.
US20100015153A1 (en) Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same
AU1583595A (en) T-cell antigens, and their use in diagnosis and treatment of t-cell mediated conditions
JPH0223156B2 (fr)
EP0241811B1 (fr) Anticorps monoclonal contre le récepteur de l'interleukine-2 humaine
FI75598C (fi) Foerfarande foer framstaellning av en monoklonal antikropp mot en maensklig tymocytantigen medelst en ny hybridcellinje.
Alvarez-Vallina et al. Delimitation of the proliferative stages in the human thymus indicates that cell expansion occurs before the expression of CD3 (T cell receptor)
Braakman et al. Expression of CD45 isoforms by fresh and activated human γδ T lymphocytes and natural killer cells
US6156882A (en) Antibody 4G8B4B12
Basel Targeting and activation of cytotoxic lymphocytes
Lobo et al. Use of anti-HLA antibodies to mask major histocompatibility complex gene products on tumor cells can enhance susceptibility of these cells to lysis by natural killer cells.
US7279291B2 (en) Polypeptides having a triggering NK activity and biological applications